Diabetes/Metabolism Research and Reviews Journal Impact Factor & Information

Publisher: Wiley

Journal description

Diabetes/Metabolism Research and Reviews is a print and electronic journal that publishes original research articles and reviews in diabetes and related areas of metabolism. The journal is dedicated to publishing papers with the shortest achievable lead times. The Editor-in-Chief and Co-Editors will consider original articles on the aetiology and pathogenesis of diabetes as well as treatment and management issues related to patient care. Areas of controversy are especially welcome. The reviews section serves the community of clinicians and researchers by providing an ongoing update of clinical and basic scientific advances in the most important areas of diabetes and metabolism.

Current impact factor: 3.59

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 3.593
2012 Impact Factor 2.968
2011 Impact Factor 3.373
2010 Impact Factor 3.094
2009 Impact Factor 2.762
2008 Impact Factor 3.149

Impact factor over time

Impact factor
Year

Additional details

5-year impact 3.16
Cited half-life 6.10
Immediacy index 1.01
Eigenfactor 0.01
Article influence 0.98
Website Diabetes/Metabolism Research and Reviews website
Other titles Diabetes/metabolism research and reviews (Online), Diabetes/metabolism research and reviews, Diabetes metabolism research and reviews
ISSN 1520-7560
OCLC 39529047
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Wiley

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • On a non-profit server
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • Zhi-Min Guo, Chuan Zhang
    [Show abstract] [Hide abstract]
    ABSTRACT: Cellular muscular aponeurotic fibrosarcoma(c-maf) is a member of the large macrophage-activating factor family. C-Maf plays important roles in the morphogenetic processes and cellular differentiation of the lens, kidneys, liver, T cells, and nervous system, and it is particularly important in pancreatic islets and erythroblastic island formation. However, the exactly role of c-Maf remains to be elucidated. In this review, we summarize the research to clarify the functions of c-maf in the cellular development and differentiation. The expression of c-Maf is higher in pancreatic duct cells than in pancreatic islet cells. Therefore, we suggest that pancreatic duct cells may be converted to the functional insulin secreting cells by regulating c-Maf. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2676
  • [Show abstract] [Hide abstract]
    ABSTRACT: The metabolic syndrome (MetS) predicts cardiovascular risk and incident type 2 diabetes mellitus (T2DM). The presence of a MetS is defined by the clustering of ≥3 out of 5 cardiometabolic criteria (hyperglycemia; hypertension; enlarged waist; low HDL-cholesterol; and hypertriglyceridemia), each of which is connected with insulin resistance (IR). It is not known whether the severity of MetS, ranked from the sextet of scores' range [0/5 to 5/5], is linearly related to reduced insulin sensitivity (IS) and/or lesser hyperbolic product across the glycemic spectrum. 839 adults (54 normoglycemic; 785 with abnormal glucose homeostasis, among whom 711 T2DM) had IS assessed together with their cardiometabolic phenotype. There was a significant gradient according to interval-scale MetS score in insulinemia; BMI; (visceral) fat; hepatic steatosis; and macroangiopathy. There was an inverse linear relationship between increasing MetS scores and decreased IS, allowing to define an IR-predicting linear equation: IS (%) = [-15.1*MetS score] + 109.4 (R(2) = 0.221). For each MetS category, mean IS values did not significantly differ between groups of patients across the glycemic spectrum. The hyperbolic product (β-cell function x IS) and/or its loss rate were inversely related to MetS severity. IS is linearly and inversely related to MetS severity across the 6 scores. This novel way to exploit information intrinsic to the MetS criteria provides an easy and costless means to quantify IS across the glycemic spectrum. Moreover, MetS severity is associated with a lesser hyperbolic product, and a higher loss of the latter. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2675
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence suggests that a history of type 2 diabetes mellitus (type 2 DM) may be involved in the development of various sites of cancer. However, the association with risk of gallbladder cancer (GBC) remains unclear. We identified studies by a literature search of MEDLINE and EMBASE through August 31, 2014, and by searching the reference lists of pertinent articles. All data were independently extracted by two investigators using a standardized data abstraction tool. Summary relative risks (SRRs) with 95% confidence intervals (CIs) were calculated with a random-effects model. A total of 20 studies (8 case-control studies and 12 cohort studies) were included in this meta-analysis. Analysis of these 20 studies found that compared with non-diabetic individuals, diabetic individuals had an increased risk of GBC (SRR = 1.56, 95% CI: 1.36-1.79). There was evidence of moderate heterogeneity among these studies (P = 0.010 and I(2) = 43.5%). This increased risk relationship is independent of smoking, body mass index and a history of gallstones. However, whether or not controlled for alcohol use may be one of the potential confounders, which significantly affect the association between type 2 DM and the risk of GBC. Diabetic women and men had a similarly increased risk of GBC associated with type 2 DM. These findings of this systematic review indicate that compared with non-diabetic individuals, individuals with type 2 DM had an increased risk of GBC development in both men and women. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2671
  • [Show abstract] [Hide abstract]
    ABSTRACT: Levels of hs-CRP and adiponectin, reflecting chronic inflammation, are associated with cardiovascular disease in type 2 diabetes. The long term effects of multifactorial therapy in type 2 diabetes patients on CRP and adiponectin are unknown. The ADDITION-NL study is a RCT among screen-detected type 2 diabetes patients, randomised to intensive treatment ( IT; HbA1c <7.0% (53 mmol/mol), blood pressure ≤135/85 mmHg, total cholesterol ≤3.5 mmol/l ) or routine care (RC). Hs-CRP and adiponectin were measured before and one, two and six years after inclusion. We analysed the effectiveness of the intervention on hs-CRP and adiponectin levels using a mixed effects model, taking into account practice, baseline levels and different medications. 424 patients were included (IT n = 235; RC n = 189). Both groups were well matched. BMI, systolic blood pressure, total cholesterol and HbA1c improved significantly more in the IT group compared to RC. Levels of hs-CRP decreased significantly in both treatment groups over time. Mean hs-CRP in the routine care group was 24% higher (p = 0.0027) than in the intensive treatment group during follow-up. After an initial increase the adiponectin values levelled off to nearly baseline values in both groups. The difference between the two groups after six years was 0.44 µg/ml (p = 0.27). Intensified multifactorial treatment in type 2 diabetes results in an enhanced decrease in hs-CRP. Whether this is clinically meaningful remains uncertain. The role of adiponectin seems to be more complex. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2669
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this work was to investigate the potential mediating effect of oxidative stress, inflammation and coagulation on Mediterranean diet- diabetes link. In 2001-02, a random sample of 1514 men (18-87 years old) and 1528 women (18-89 years old) was selected to participate in the ATTICA study, where Athens is a major metropolis. A validated questionnaire was used to assess lifestyle and dietary factors. Adherence to Mediterranean diet was recorded using MedDietScore. Among others, oxidative stress and inflammatory biomarkers were recorded. During 2011-2012, the 10-year follow-up was performed. Diabetes incidence was defined according to American Diabetes Association criteria. 191 incident cases of diabetes were documented, yielding to an incidence of 12.9% (13.4% in men and 12.4% in women). Medium and high adherence were found to decrease diabetes risk by 49% (95%CI: 0.30, 0.88), and 62% (95%CI: 0.16, 0.88) respectively, compared to low adherence. A logarithmic trend between Mediterranean diet and diabetes incidence was also revealed (p for trend = 0.042). Individuals with abnormal waist circumference (>94 for men, >80 for women) were benefited the most. Wholegrain cereals, fruits and legumes had the greatest predictive ability. The anti-diabetic effect of Mediterranean diet was mediated by TNF-α, homocysteine and TAC. The reported results underline the role of Mediterranean diet as a promising dietary tool for the primary prevention of diabetes, by attenuating inflammation and fostering TAC; thus, this dietary pattern may have a therapeutic potential for a plethora of cardio-metabolic disorders, resulting from inflammation and/or oxidative stress. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2672
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the role of common variants in the genes SLC30A8, KCNQ1, and TCF7L2 in the association between birth weight and increased risk of type 2 diabetes in Han Chinese. Seven variants (SLC30A8- rs13266634 and rs2466293; KCNQ1- rs2237895 and rs2074196; and TCF7L2- rs11196218, rs7903146, and rs290487) were genotyped in 1,181 individuals born in Peking Union Medical College Hospital from 1921 to 1954 by Taqman allelic discrimination assay. All the subjects were stratified by birth weight into groups of ≥3000 g and <3000 g. Associations of genetic variants with birth weight and with risk of type 2 diabetes and impaired glucose tolerance (together as impaired glucose metabolism, IGM) were analyzed. After adjustment for sex, gestational weeks, parity, and maternal age, the G allele of KCNQ1-rs2074196 was associated with higher birth weight (p = 0.032). KCNQ1-rs2074196, rs2234895, and TCF7L2-rs290487 were associated with increased risk of IGM. However, the associations were modified by size at birth. The associations above were only found in subjects with birth weights greater than (or equal to) 3000 g. In subjects with birth weights less than 3000 g, IGM was associated with variants SLC30A8-rs2466293 and TCF7L2-rs11196218. The role of common variants in susceptible genes in the development of IGM was modified by birth weight in Han Chinese. This provides evidence that genetic variants influence birth weight and are involved in development of type 2 diabetes. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2670
  • [Show abstract] [Hide abstract]
    ABSTRACT: The proposed 2015 United States Preventive Services Task Force guidelines recommend diabetes screening for individuals ≥45 years or demonstrating other risk factors for dysglycemia. Still, many patients with dysglycemia remain undiagnosed and opportunities for early intervention are lost. To test novel approaches for diagnosis using a Hemoglobin A1c (HbA1c ) test, we screened adult patients who were admitted to an observation unit from the emergency department with no known history of pre-diabetes or diabetes. Of 256 subjects, 9% were newly diagnosed with diabetes and 52% were newly diagnosed with pre-diabetes. Of those aged 18-29 years, 33% were newly diagnosed with dysglycemia, while 55% of those aged 30-44 years and 70% of those aged ≥45 years were newly diagnosed with dysglycemia. Our results suggest that regardless of age, large proportions of patients in the emergency department observation unit have undiagnosed dysglycemia, an important finding given the large number of observation admissions. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2674
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Growing evidence suggests the presence of a complex interplay between hypertension as well as type 2 diabetes mellitus (DM) and osteoporosis. The present study was designed to investigate a possible impact of type 2 DM on bone remodeling markers such as osteoprotegerin (OPG) and N-terminal propeptide of type 1 collagen (P1NP) in hypertensive patients.Design and Methods The 100 study participants were divided into three groups according to presence of DM and hypertension: group one included diabetic hypertensive subjects, group 2 included hypertensive subjects without diabetes and group 3 included subjects without hypertension and DM (controls). Blood sampling for metabolic parameters, including OPG, P1NP, adiponectin, fasting glucose, HbA1C, CRP, HOMA-IR, HOMA-beta function was performed.ResultsCirculating P1NP increased from Group 1 to Group 3 in a continuous fashion. P1NP was significantly lower in hypertensive subjects with DM (Group 1), than in Group 2 and 3 (p < 0.0001). P1NP, was marginally lower in diabetic hypertensive subjects as compared to nondiabetics with hypertension (p = 0.079). Circulating OPG did not differ significantly between groups (p = 0.593).Conclusions In the present study, bone formation marker, PINP, was significantly lower in diabetic hypertensive subjects as compared to nondiabetics with and without hypertension. P1NP was inversely associated with parameters of glucose homeostasis such as fasting glucose, HBA1C and positively with HOMA-beta cell function. Type 2 DM was associated with an adverse effect on bone formation independently of age, sex and exposure to antidiabetic drugs. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2668
  • [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes is a complex and multifaceted disease requiring an individualized approach. A special attention, in treating the patients, should be devoted to the presence of comorbidities like overweight or obesity and arterial hypertension. Among the available anti-hyperglycemic agents, several are associated with side effects like hypoglycaemia and weight gain. An increasing interest is reported in SGLT2 inhibitors, a relatively novel class of glucose-lowering drugs that act independently of insulin, provide benefits beyond glucose-lowering actions, and show a better tolerability compared with traditional medications for type 2 diabetes. This review tries to offer a balanced view on the main extra-glycemic effects of empagliflozin, also mentioning clinical data obtained with other SGLT2 inhibitors; the role of the proximal tubule in the pathophysiology of diabetic nephropathy and the potential nehroprotection exerted by this compound are also briefly discussed. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2666
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic syndrome (MetS) appears closely linked with ceramide accumulation inducing insulin resistance and toxicity to multiple cell types. Animal studies demonstrate that thiazolidinediones (TZDs) reduce ceramide concentrations in plasma and skeletal muscle and support lowering of ceramide levels as a potential mediator of TZDs' mechanism of action in reducing insulin resistance; however, studies in humans have yet to be reported. This study investigated the effects of pioglitazone therapy on plasma ceramides to understand the mechanism by which TZDs improve insulin resistance in MetS. 37 subjects with MetS were studied in a single-center, randomized, double-blind, placebo-controlled, trial comparing pioglitazone to placebo. Data were collected at baseline and after 6 months of therapy. The primary endpoint was the change from baseline in plasma ceramide concentrations. Treatment with pioglitazone for 6 months, compared to placebo, significantly reduced multiple plasma ceramide concentrations: C18:0 (p = .001), C20:0 (p = .0004), C24:1 (p = .009), dihydroceramide C18:0 (p = .005), dihydroceramide C24:1 (p = .004), lactosylceramide C16:0 (p = .02) and the hexosylceramides C16:0 (p = .0003), C18:0 (p = 0.00001), C22:0 (p = .00002) and C24:1 (p = .0006). Additionally, significant reductions were found when ceramides were grouped by species: ceramides (p = .03), dihydroceramides (p = .02), hexosylceramides (p = .00001), and lactosylceramides (p = .02). The total of all measured ceramides was also significantly reduced (p = .001). Following treatment with pioglitazone, the decrease in some ceramide species correlated negatively with the change in insulin sensitivity (dihydroceramide C16:0, r = -.54; p = .02), and positively with total (lactosylceramide C24:0, r = .53; p = .02) and high molecular weight (lactosylceramide C24:0, r = .48; p = .05) adiponectin measurements; however, significant associations with changes in liver fat and glycemic control reduction were not found. Pioglitazone in individuals with MetS induces a potent decrease in plasma ceramides, and some of the changes correlate with changes in insulin resistance and adiponectin levels. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2662
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bariatric surgery is a new emerging treatment that demonstrates a favorable effect on type 2 diabetes, although its underling mechanisms still remain unknown. After receiving bariatric surgery, beta cells undergo the process of rebirth, which involves apoptosis evasion, regeneration and improved beta cell function. Therefore, further studies are necessary to elucidate how bariatric surgery can resolve type 2 diabetes. Here, our review focuses mainly on beta cells, the insulin-generating cells, whose biological features change dramatically after bariatric surgery. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2663
  • [Show abstract] [Hide abstract]
    ABSTRACT: Circulating microRNA 130b has been closely associated with multiple diseases such as tumor, obesity and diabetes mellitus in human. However, there was no study addressed the expression of circulating miR-130b in patients with diabetic nephropathy (DN). This study evaluates the correlation between serum miR-130b and the severity of diabetic nephropathy determined by urinary albuminuria. 327 patients with type 2 diabetes mellitus (T2DM) were divided into three groups: normoalbuminuria group (DM, UACR <30 mg/g, n =137); microalbuminuria group (DN1, UACR 30-300 mg/g, n = 122) and macroalbuminuria group (DN2, UACR > 300 mg/g, n = 68). The levels of serum miR-130b were validated by real-time polymerase chain reaction. Serum transforming growth factor-β1 (TGF-β1), hypoxia inducible factor 1α (HIF-1α) and fibronectin (FN) were determined by enzyme-linked immunosorbent assay (ELISA). Compared with control, serum miR-130b levels were significantly decreased in T2DM patients and gradually decreased in the patients of DM, DN1 and DN2 groups, (P < 0.001). Furthermore, Age, sex-adjusted regression analyses showed that decreased level of serum miR-130b, increased levels of HbA1c, HOMA-IR, TG, LDL, Scr, BUN, TGF-β1, HIF-1α and FN were significantly correlated with UACR, (P < 0.05). In addition, serum miR-130b levels inversely correlated with HbA1c, HOMA-IR, TG, LDL, Scr, BUN, TGF-β1, HIF-1α and FN (P < 0.05). Our findings suggest that serum miR-130b may be a new biomarker of the early diagnosis of DN in T2DM. Circulating miR-130b may be involved in the pathological mechanism of DN, such as lipid metabolic disorders, oxidative stress, extracellular matrix deposition and renal fibrosis. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2659
  • [Show abstract] [Hide abstract]
    ABSTRACT: Irisin, as a newly discovered hormone-like myokine detected in the presence of exercise-induced PGC-1α, plays an important role in energy metabolism on each organ in the body and regulation of metabolic diseases such as obesity and diabetes, which can contribute to the exploration of the novel and effective therapeutic targets or therapeutic strategies of these metabolic diseases or metabolism-associated health issues. To date, little is known regarding the functions and regulatory mechanisms of irisin with respect to metabolic diseases or metabolism-associated health issues. In this narrative review article, we will systematically introduce the structural characteristics, production and distribution in tissues and organs, and regulation and corresponding mechanisms for metabolic diseases or metabolism-associated health issues of irisin. Meanwhile, its future prospects and the development of irisin-related products for the promotion of human health have also been proposed, which will be benefit for the future research and application of irisin. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2660
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the efficacy and safety of once-daily insulin glargine plus gliclazide modified release (MR) combination therapy versus twice-daily premixed insulin monotherapy in Chinese type 2 diabetic patients insufficiently controlled by oral antidiabetic agents (OADs). In a 12-week, multicenter, randomized, parallel group clinical trial, patients with poor glycemic control (fasting plasma glucose ≥7.0 mmol/L and 7.5% < hemoglobin A1c (A1C) ≤10%) on OADs were randomized to the treatment groups for combination therapy (n = 52) or monotherapy (n = 53). Continuous glucose monitoring were carried out over two 72-h periods, at the beginning and the end of the study, and the data was used to calculate the 24 h mean blood glucose (24 h MBG), mean amplitude of glycemic excursions (MAGE), standard deviation of blood glucose (SDBG), and the mean of daily differences (MODD). The mean A1C decrease from baseline to study end was significant for both treatment groups (combination therapy: -1.23 ± 0.92%; insulin monotherapy: -1.02 ± 1.04%); moreover, the combination therapy group showed a significantly more robust A1C decrease (P = 0.0308). Both therapies significantly reduced the 24 h MBG (both, P < 0.001), but neither produced a significant effect on glycemic variability, calculated as MAGE, SDBG, and MODD. In addition, the effects on rates of hypoglycemic episodes were similar between the two therapies. Chinese patients with type 2 diabetes inadequately controlled with OADs attained greater benefit from once-daily insulin glargine plus gliclazide MR regimen than from a twice-daily premixed insulin regimen. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2661
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults (LADA) and type 2 diabetes. This is a cross-sectional study. Our diabetes registry included 6,975 patients aged 30 to 75 years-old with phenotypic type 2 diabetes who underwent islet autoantibody screening between 2003 and 2012; 384 patients were identified to have LADA. Rates of chronic complications for LADA and type 2 diabetes were compared using a 1:2 matched design. Logistic models were fitted to identify the presence of diabetic chronic complications using clinical characteristics including gender, age, duration of diabetes, glycemic control and metabolic syndrome. When duration of diabetes <5 years, the prevalence of diabetic nephropathy (DN; 12.2% vs. 21.8%, P = 0.018) and diabetic retinopathy (DR; 8.1% vs. 15.9%, P = 0.011) were significantly lower in patients with LADA than patients with type 2 diabetes; the prevalence of DN and DR were comparable between both groups when duration ≥5 years. There was no significant difference in the prevalence of macrovascular complications between groups. The areas under the receiver operating characteristic curves (AUCs) based on the DN and DR models were larger for LADA than type 2 diabetes (0.72 vs. 0.61, P = 0.013; 0.76 vs. 0.68, P = 0.056). Patients with LADA had a lower prevalence of microvascular complications than patients with type 2 diabetes when the duration of diabetes was <5 years. Regression equation fitted by clinical characteristics can better predict the risk of microvascular complications in LADA than in type 2 diabetes. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; 31(4). DOI:10.1002/dmrr.2626
  • [Show abstract] [Hide abstract]
    ABSTRACT: for Research Article and other types| Summary for Review Article|Background Literature suggests that persons with type 2 diabetes (T2DM) are at risk for cognitive impairment, hence dementia. Common domains reported to be affected in those with T2DM are memory and executive functions. The extent of influence of T2DM on these domains has varied over studies. A systematic review and meta-analysis was carried out to understand whether sub-domains contributed to the variations observed in published research.Methods We searched PubMed”, ScienceDirect”, “SciVerseHub”, “Psychinfo”, “Proquest” “Ebsco” and “J-gate Plus” databases for published studies on cognition and T2DM among persons aged 50 years and older. Memory, executive functions and processing speed domain and sub-domain scores were extracted and effect sizes (Cohen's d) were calculated and analysed.Results817 articles were found, and after various levels of filtering 15 articles met the inclusion criteria for quantitative analyses. The analyses indicated that in comparison to controls, persons with T2DM showed decrements in episodic memory (d = -0.51), logical memory (d = -0.24), decrements in sub-domain of executive functions which included phonemic fluency (d = -0.35) & cognitive flexibility (d = 0.52), and speed of processing (d = -0.22). We found no difference in the sub-domains of verbal short term memory and working memory.DiscussionThe meta-analysis revealed a detrimental effect of T2DM on cognitive sub domains namely episodic memory and cognitive flexibility. There was a trend for the logical memory, phonemic fluency and processing speed to be affected. The analysis indicates that T2DM is a detrimental factor on certain cognitive sub-domains, rendering the person vulnerable to subsequent dementia. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2664